IRIS PubliCatt

Pugliese, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.718
EU - Europa 1.482
AS - Asia 455
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 3.672
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.708
DE - Germania 457
SE - Svezia 349
IT - Italia 191
CN - Cina 172
SG - Singapore 134
IE - Irlanda 111
FR - Francia 92
UA - Ucraina 88
ID - Indonesia 71
GB - Regno Unito 69
IN - India 36
RU - Federazione Russa 36
FI - Finlandia 30
PL - Polonia 16
IR - Iran 11
KR - Corea 11
TR - Turchia 11
CI - Costa d'Avorio 10
BE - Belgio 9
CA - Canada 9
NL - Olanda 8
CZ - Repubblica Ceca 7
ES - Italia 6
AT - Austria 4
BG - Bulgaria 3
JP - Giappone 3
A2 - ???statistics.table.value.countryCode.A2??? 2
HU - Ungheria 2
AR - Argentina 1
CH - Svizzera 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
NG - Nigeria 1
PH - Filippine 1
PT - Portogallo 1
SC - Seychelles 1
TN - Tunisia 1
TW - Taiwan 1
VN - Vietnam 1
Totale 3.672
Salva come PNG Salva come JPEG
Città #
Chandler 451
Ashburn 179
Dublin 108
Singapore 97
New York 93
Jacksonville 77
Jakarta 71
San Mateo 61
Dearborn 54
Ann Arbor 44
Cattolica 43
Milan 36
Boston 34
Princeton 34
Beijing 30
Nürnberg 30
Wilmington 30
Moscow 29
Nanjing 29
Marseille 27
Los Angeles 25
Munich 24
Bremen 23
Houston 23
Rome 23
Boardman 17
Lawrence 17
Fairfield 15
Redwood City 14
Lancaster 13
Seattle 12
Shenyang 12
Warsaw 12
Izmir 11
Seoul 11
Abidjan 10
Leawood 10
Nanchang 10
Woodbridge 10
Augusta 9
Brussels 9
Detroit 9
Washington 8
Cagliari 7
Jiaxing 7
Norwalk 7
Brno 6
Hebei 6
Lappeenranta 6
Mountain View 6
Pune 6
Sacramento 6
Andover 5
Hefei 5
Helsinki 5
London 5
Tianjin 5
Ardabil 4
Cambridge 4
Edinburgh 4
Guasila 4
Kish 4
San Diego 4
Toronto 4
Vienna 4
Atlanta 3
Changchun 3
Changsha 3
Chelsea 3
Costa Mesa 3
Fremont 3
Madrid 3
Miami 3
Millbury 3
Paris 3
San Jose 3
Shanghai 3
Sofia 3
University Park 3
A Coruña 2
Amsterdam 2
Ancona 2
Busto Arsizio 2
Cento 2
Collegeville 2
Florence 2
Jinan 2
Kashan 2
Kraków 2
Kunming 2
Lille 2
Monmouth Junction 2
Montreal 2
Mumbai 2
Napoli 2
Pavia 2
Portocannone 2
Raritan 2
Redmond 2
Romainville 2
Totale 2.082
Salva come PNG Salva come JPEG
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 152
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 142
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 141
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 134
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 134
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 131
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 118
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 111
Ileal Crohn's disease: CEUS determination of activity 102
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 102
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 97
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 86
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 82
Management of perianal fistulas in Crohn's disease: an up-to-date review 73
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 73
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 69
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 67
Adalimumab in active ulcerative colitis: a "real-life" observational study 65
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 64
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 62
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 60
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 60
Frontiers in drug research and development for inflammatory bowel disease 58
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 57
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 56
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 55
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 54
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 54
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 52
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 51
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 50
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report 50
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 49
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 49
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 49
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 46
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 45
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 45
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 43
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 40
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 39
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 38
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 38
Reply to managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers 37
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 37
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 37
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 37
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 36
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 35
Diet and nutrients in gastrointestinal chronic diseases 34
Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study 33
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 32
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 32
Radiomics could predict surgery at 10 years in Crohn's disease 31
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab 29
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 27
Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report 24
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 20
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 19
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease 18
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 15
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 13
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 12
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 11
Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 10
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 10
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 10
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 7
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 7
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 5
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 5
Totale 3.766
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020313 0 0 37 15 28 54 28 20 28 10 58 35
2020/2021252 13 20 5 28 31 14 16 10 32 10 62 11
2021/2022458 37 19 8 70 8 10 10 65 9 25 90 107
2022/20231.127 148 147 78 182 71 130 54 103 143 15 36 20
2023/2024767 18 161 30 72 23 126 45 48 41 39 72 92
2024/2025186 20 43 123 0 0 0 0 0 0 0 0 0
Totale 3.766